NCT05134610

Brief Summary

For patients undergoing colorectal surgery, post-operative pulmonary complications (PPCs) are common. PPCs are associated with increased morbidity and mortality, as well as prolonged hospital stays and healthcare costs. Pulmonary exercise in the pre-operative setting is thought to improve pulmonary fitness and decrease incidence of PPCs. Use of an oscillating positive expiratory pressure (OPEP) device sees patients improve their respiratory fitness through prescribed usage of a handheld instrument that exercises pulmonary muscles while breathing. Here, the investigators propose a pilot randomized-controlled trial (RCT) to evaluate the feasibility of a large scale study that would examine the effect of preoperative OPEP device exercises in preventing PPCs for patients undergoing elective colorectal surgery.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 14, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 26, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

March 1, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2023

Completed
Last Updated

January 14, 2022

Status Verified

January 1, 2022

Enrollment Period

1.6 years

First QC Date

November 14, 2021

Last Update Submit

January 11, 2022

Conditions

Keywords

oscillating pulmonary expiratory pressure therapyOPEP

Outcome Measures

Primary Outcomes (4)

  • Trial feasibility: capacity for recruitment

    Ability of clinics to recruit patients in a timely manner. To be reported as a percent of the desired number of patients recruited over an 18 month period.

    18 months

  • Trial feasibility: device adherence

    Adherence of enrolled patients to usage of the OPEP device. To be reported as percent of patients returning a complete logbook detailing their consistent use of the OPEP device pre-op and post-op.

    18 months

  • Trial feasibility: data collection

    3\) Completeness of data collected from enrolled patients medical record. To be reported as a percent of recruited patients with complete datasets following the trials completion. Used to identify gaps in data for a future fully powered trial.

    18 months

  • Trial feasibility: limited efficacy of the OPEP device

    Limited efficacy of the OPEP device to decrease post-operative pulmonary complications (PPCs). PPCs represents a composite outcome including atelectasis, pneumonia, prolonged requirement for supplemental oxygen, and respiratory failure.

    18 months

Study Arms (2)

Control

NO INTERVENTION

Standard of care for pre- and post-op pulmonary care

OPEP Therapy

EXPERIMENTAL

14 days pre- and and post-op OPEP device usage

Device: AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE

Interventions

Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery

OPEP Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must be 18 years of age or older, and scheduled for an elective colorectal procedure at London Health Science Center (LHSC). Informed consent must be obtained.

You may not qualify if:

  • Patients unable to perform written consent will be excluded. The investigators will not include colorectal procedures performed for urgent or emergent indications. Patients with advanced pulmonary disease necessitating home oxygen pre-operatively will be excluded. Patients that are pregnant will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Jeff Metz, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

November 14, 2021

First Posted

November 26, 2021

Study Start

March 1, 2022

Primary Completion

October 1, 2023

Study Completion

October 1, 2023

Last Updated

January 14, 2022

Record last verified: 2022-01